Open horizons

CSCO joins ESMO Open—Cancer Horizons

Correspondence to Dr Christoph C Zielinski; christoph.zielinski@ meduniwien.ac.at ESMO Open—Cancer Horizons is happy to announce its association with the Chinese Society of Clinical Oncology (CSCO). After intensive personal contacts between the CSCO President Professor Y-LW and the leadership of the European Society for Medical Oncology (ESMO) as well as the Editor-in-Chief of ESMO Open—Cancer ...

Rituximab biosimilars open new horizons in immunotherapy

ESMO Open—Cancer Horizons and the future of oncology

Correspondence to Professor Christoph C Zielinski; christoph.zielinski@ meduniwien.ac.at In recent years we have witnessed an almost complete repositioning of oncology. Our understanding of the basic biology of the disease has evolved, as has our view of cancers that were once considered as a single entity and are now known to be composed of a wide variety of molecular subgroups. In tandem, the...

Magnetoliposomes open up new horizons as MRI contrast agents

Introduction High resolution MRI has a low sensitivity for the visualization of low cell numbers in vivo. This is circumvent by the internalization of high concentrations of superparamagnetic iron oxide particles resulting in potential cytotoxic effects or affecting cell biology like differentiation, formation of ROS etc. [1]. In addition, the ability to monitor iron oxide labelled cells in viv...

AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open

Correspondence to Professor Christoph C Zielinski, christoph.zielinski@ meduniwien.ac.at ESMO Open—Cancer Horizons has experienced remarkable success since its first issue in January 2016. To date, we have published 41 articles and have now applied for indexing in PubMed Central. Coupled with the unrestricted open access policy, this will increase the visibility of all our published articles an...